In a filing, Celldex Therapeutics Inc. revealed its SVP OF REGULATORY AFFAIRS Heath-Chiozzi Margo unloaded Company’s shares for reported $1.96 million on Jun 03 ’24. In the deal valued at $33.65 per share,58,369 shares were sold. As a result of this transaction, Heath-Chiozzi Margo now holds 13,383 shares worth roughly $0.47 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Wright Richard M. sold 46,844 shares, generating $1,579,353 in total proceeds. Upon selling the shares at $33.72, the SR. VP & CCO now owns 20,833 shares.
Before that, Jimenez Freddy A. sold 8,006 shares. Celldex Therapeutics Inc. shares valued at $269,002 were divested by the SVP & GENERAL COUNSEL at a price of $33.60 per share. As a result of the transaction, Jimenez Freddy A. now holds 25,924 shares, worth roughly $0.91 million.
TD Cowen initiated its Celldex Therapeutics Inc. [CLDX] rating to an Outperform in a research note published recently. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who increased its forecast for the stock in early November from “an Underweight” to “an Equal weight”. Wells Fargo began covering CLDX with “an Underweight” recommendation on August 22, 2023. Jefferies started covering the stock on September 17, 2021. It rated CLDX as “a Buy”.
Price Performance Review of CLDX
On Friday, Celldex Therapeutics Inc. [NASDAQ:CLDX] saw its stock jump 0.48% to $35.28. Over the last five days, the stock has gained 5.95%. Celldex Therapeutics Inc. shares have fallen nearly -11.04% since the year began. Nevertheless, the stocks have risen 0.14% over the past one year. While a 52-week high of $53.18 was reached on 03/04/24, a 52-week low of $22.11 was recorded on 06/04/24. SMA at 50 days reached $38.36, while 200 days put it at $34.90. A total of 0.92 million shares were traded, compared to the trading of 0.67 million shares in the previous session.
Levels Of Support And Resistance For CLDX Stock
The 24-hour chart illustrates a support level at 34.70, which if violated will result in even more drops to 34.12. On the upside, there is a resistance level at 35.86. A further resistance level may holdings at 36.44. The Relative Strength Index (RSI) on the 14-day chart is 43.40, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.74, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 53.81%. Stochastics %K at 30.52% indicates the stock is a holding.
The most recent change occurred on September 10, 2021 when SVB Leerink began covering the stock and recommended ‘”an Outperform”‘ rating along with a $68 price target.
